Drug GMP “Surveillance” Will Link Compliance Information To Inspections

CDER Director Janet Woodcock says a new database will drive risk-based inspection decisions. Once active and combined with new objective quality measurement data, the system should allow all relevant agency personnel access to the same information in the hopes of improving oversight.